AUTHORS
Guillermo Montalban-Bravo, MD, Somedeb Ball, MD2, Abhishek Avinash Mangaonkar, MBBS3, David Sallman, MD4, Gabriel Mannis I, MD5, Peter L Greenberg, MD6, Curtis Lachowiez, MD7, Richard Stone, MD8, Ewelina Morawa, MD9, Marissa Timothy, MS10, Jennifer O'Neil, PhD11, Brandon Turunen, PhD12, Philip J Vickers, PhD13, Alonzo Martinez, PhD14, Sergio Santillana, MD, PhD15, Courtney DiNardo, MD, MSCE16, Michael R. Savona, MD17, Mrinal M. Patnaik, MD, MBBS18, Eric Padron, MD19
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, United States
2 Vanderbilt University Medical Center, Nashville, United States
3 Mayo Clinic, Rochester, United States
4 Moffitt Cancer Center, Tampa, United States
5 Stanford Medicine, Stanford, United States
6 Stanford Medicine, Stanford, United States
7 OHSU, Portland, United States
8 Dana-Farber Cancer Institute, Boston, United States
9 Solu Therapeutics, Boston, United States
10 Solu Therapeutics, Boston, United States
11 Solu Therapeutics, Boston, United States
12 Solu Therapeutics, Boston, United States
13 Solu Therapeutics, Boston, United States
14 Solu Therapeutics, Boston, United States
15 Solu Therapeutics, Boston, United States
16 MD Anderson Cancer Center, Houston, United States
17 Vanderbilt University Medical Center, Nashville, United States
18 Mayo Clinic, Rochester, United States
19 Moffitt Cancer Center, Tampa, United States
ABSTRACT
Background
CMML is a myeloid neoplasm characterized by classical monocytosis, marrow dysplasia, splenomegaly, and a propensity for acute myeloid leukemia (AML) transformation. Clonal classical (M01) monocytes in CMML express high levels of C-C chemokine receptor (CCR2), which promotes malignant monocyte survival. Single-cell profiling identifies CCR2 as a highly expressed target on malignant monocytes and aberrant hematopoietic monocytic progenitors. STX-0712 is a first-in-class CCR2-targeted CyTAC that combines a humanized ADCC-enhancing monoclonal antibody with a CCR2-directed small molecule to selectively eliminate malignant monocytes and monocytic progenitors through NK cell-mediated effector killing. We report initial results from the ongoing, multicenter, open-label, first-in-human phase 1 study of STX-0712 in patients with refractory/resistant CMML. A second cohort of patients of relapsed/refractory monocytic or monocytic predominant AML is planned to open.
Methods
The study design includes dose-escalation and dose-expansion. Dose escalation utilizes a BOIN design. Primary objectives are safety, tolerability, dose-limiting toxicities (DLTs), and determining the recommended phase 2 dose (RP2D). Secondary objectives include pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. STX-0712 is administered as a single intravenous infusion, and tested in two schedules; 3 weeks (Q3W), and 2 weeks (Q2W). Three dose levels (DL) have been evaluated to date: Of these, DL1 was evaluated every 3 weeks (Q3W), and DL2 and DL3 were evaluated at Q3W and Q2W. Four patients have been treated at DL1 (Q3W), 3 at DL2 (Q3W), 4 at DL2 (Q2W), 6 at DL3 (Q3W), and 2 at DL3 (Q2W). Due to early cytokine release syndrome (CRS) events, premedication with dexamethasone is administered before each dose. Step-up dosing, introduced after DL1, is used during cycle 1 only and consists of a priming dose administered 3 days before the full dose. Responses were assessed according to the MDS/MPN IWG 2015 criteria.
Results
As of the data cutoff (July 06, 2026), 19 patients (pts) had received STX-0712, with the first pt being dosed on March 13, 2025. Median age was 73 years (range, 61-82); 16 (84.2%) were male, 3 (15.8%) were female and all pts were White. All pts were either primary refractory or relapsed after at least four cycles of hypomethylating agents or hydroxyurea (for proliferative CMML). Most common treatment-related adverse events (TRAEs) included CRS; 13/19 pts [68.4%], 26 events, all grade 1 [n=19] or grade 2 [n=7] and infusion-related reactions (IRRs; 9/19 pts [47.4%], 28 events, all grade 1 [n=12] or grade 2 [n=16]). No tumor lysis syndrome (TLS), immune effector cell-associated neurotoxicity syndrome (ICANS), or DLTs have been observed. Treatment-related SAEs occurred in 7/19 pts (36.8%) and included CRS (n=4; two grade 1 and two grade 2), IRRs (n=2; both grade 2), and anemia (n=1; grade 3). No grade >3 CRS or IRRs, treatment-related deaths, or treatment discontinuation due to TRAEs were observed. Three pts received tocilizumab for CRS. Fifteen of 19 (79%) pts were response-evaluable. Four pts have not yet reached their first scheduled disease assessment. The ORR was 33.3% (5/15) among response-evaluable pts, including one complete remission, three optimal marrow responses, and one clinical benefit (erythroid response). One optimal marrow response at DL1 was maintained for 36 weeks. DL2 has an ongoing marrow response for 12 weeks, and DL3 has a CR that is ongoing at 7 weeks. Two pts with progressive disease were reported. PK showed dose proportional increase in exposure. No drug accumulation has been observed. Consistent with robust target engagement, all 19 pts achieved rapid and profound monocyte depletion. Translational data including ongoing longitudinal single cell multiomic studies measuring composition of CCR2 positive progenitors and immune microenvironment to determine the CCR2 positive target cells will be analyzed.
Conclusions
STX-0712 was generally well tolerated with no DLTs observed across evaluated dose levels. CRS and IRR were manageable and limited to grade 1/2 events. Preliminary evidence of robust target engagement and encouraging early antileukemia activity in both peripheral blood and bone marrow, including durable responses across all DLs evaluated to date and one ongoing complete remission and optimal marrow response, supports continued dose escalation in CMML.
Clinical Trial. Information : NCT06950034
DISCLOSURES
Guillermo Montalban-Bravo, MD: Solu Therapeutics - Research Funding; Rigel Pharmaceuticals - Research Funding; Takeda Oncology - Research Funding